CRISPR-Cas guides the future of genetic engineering
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The diversity, modularity, and efficacy of CRISPR-Cas systems are driving a biotechnological revolution. RNA-guided Cas enzymes have been adopted as tools to manipulate the genomes of cultured cells, animals, and plants, accelerating the pace of fundamental research and enabling clinical and agricultural breakthroughs. We describe the basic mechanisms that set the CRISPR-Cas toolkit apart from other programmable gene-editing technologies, highlighting the diverse and naturally evolved systems now functionalized as biotechnologies. We discuss the rapidly evolving landscape of CRISPR-Cas applications, from gene editing to transcriptional regulation, imaging, and diagnostics. Continuing functional dissection and an expanding landscape of applications position CRISPR-Cas tools at the cutting edge of nucleic acid manipulation that is rewriting biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR-Cas9 and related enzymes have been used to manipulate the genomes of cultured cells, animals and plants, vastly accelerating the pace of fundamental research and enabling breakthroughs in agriculture and synthetic biology (reviewed in refs. 6-9).”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Self-citationMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aar6245 · Cited by 4,507
Self-citationProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Nucleic acid detection with CRISPR-Cas13a/C2c2
Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., Verdine, V., Donghia, N., Daringer, N. M., Freije, C. A., et al. (2017) · Science · doi:10.1126/science.aam9321 · Cited by 3,844
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Research works printed but not linked: 3
- 47. Rousseau BA, Hou Z, Gramelspacher MJ, Zhang Y, Mol. Cell (2018), doi:10.1016/j.molcel. 2018.01.025. · doi:10.1016/j.molcel
- 63. Chen JS, Ma E, Harrington LB, Tian X, Doudna JA, bioRxiv, 226993 (2017).
- 71. Charlesworth CT et al., bioRxiv, 243345 (2018).
Cited by
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“123 – 125 Recently, novel nuclease Cas13a has been shown to preferentially bind and cleave RNA rather than DNA substrates, further expanding the CRISPR toolbox.”
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Self-citationCRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
“Furthermore, this line of research showedhowCRISPR’s RNA-programmed cutting action (5, 6) could be used to alter DNA sequences in any cell with unprecedented ease [reviewed in (7)].”
BackgroundSelf-citationCytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos
Zuo, E., Sun, Y., Wei, W., Yuan, T., Ying, W., Sun, H., Yuan, L., Steinmetz, L. M., Li, Y., & Yang, H. (2019) · Science · doi:10.1126/science.aav9973 · Cited by 782
Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing
Nuñez, J. K., Chen, J., Pommier, G. C., Cogan, J. Z., Replogle, J. M., Adriaens, C., Ramadoss, G. N., Shi, Q., Hung, K. L., Samelson, A. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.025 · Cited by 760
“In particular, clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) and other CRISPR systems can be programmed with a single guide RNA (sgRNA) to introduce DNA breaks at a specified site to inactivate gene function or to stimulate precise DNA editing by homology-directe…”
BackgroundPast, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
“12,18 Cas9 forms an active nuclease in association with either crRNA-tracrRNA complexes or sgRNA guides.”
CRISPR-CasΦ from huge phages is a hypercompact genome editor
Pausch, P., Al-Shayeb, B., Bisom-Rapp, E., Tsuchida, C. A., Li, Z., Cress, B. F., Knott, G. J., Jacobsen, S. E., Banfield, J. F., & Doudna, J. A. (2020) · Science · doi:10.1126/science.abb1400 · Cited by 555
Self-citationRegulatory R-loops as facilitators of gene expression and genome stability
Niehrs, C., & Luke, B. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0206-3 · Cited by 529
Functionally diverse type V CRISPR-Cas systems
Yan, W. X., Hunnewell, P., Alfonse, L. E., Carte, J. M., Keston-Smith, E., Sothiselvam, S., Garrity, A. J., Chong, S., Makarova, K. S., Koonin, E. V., et al. (2019) · Science · doi:10.1126/science.aav7271 · Cited by 518
Ko, Y.-S., Kim, J. W., Lee, J. A., Han, T., Kim, G. B., Park, J. E., & Lee, S. Y. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00155d · Cited by 476
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 404
Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice
Zhou, H., Su, J., Hu, X., Zhou, C., Li, H., Chen, Z., Xiao, Q., Wang, B., Wu, W., Sun, Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.024 · Cited by 437
“A recently characterized RNA-guided and RNA-targeting CRISPR protein family known as Cas13 offers an efficient approach for manipulation of RNA transcripts (Abudayyeh et al., 2016; Cox et al., 2017; East-Seletsky et al., 2016; Gootenberg et al., 2017; Knott and Doudna, 2018; Konermann et al., 2018).”
PnB Designer: a web application to design prime and base editor guide RNAs for animals and plants
Siegner, S. M., Karasu, M. E., Schröder, M. S., Kontarakis, Z., & Corn, J. E. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04034-6 · Cited by 430
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis
Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00414-2 · Cited by 401
Analytical characterization of liposomes and other lipid nanoparticles for drug delivery
Fan, Y., Marioli, M., & Zhang, K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113642 · Cited by 395
Yang, X., Tang, Q., Jiang, Y., Zhang, M., Wang, M., & Mao, L. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11996 · Cited by 403
How genomics can help biodiversity conservation
Theissinger, K., Fernandes, C., Formenti, G., Bista, I., Berg, P. R., Bleidorn, C., Bombarely, A., Crottini, A., Gallo, G. R., Godoy, J. A., et al. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.005 · Cited by 401
“Genome editing: engineering adaptation, gene drives, and de-extinction Genome-editing tools, such as CRISPR-Cas9 [104], allow precise modi fi cation of genes and genomes of living organisms.”
BackgroundBiosynthetic potential of the global ocean microbiome
Paoli, L., Ruscheweyh, H.-J., Forneris, C. C., Hubrich, F., Kautsar, S., Bhushan, A., Lotti, A., Clayssen, Q., Salazar, G., Milanese, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04862-3 · Cited by 384
Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373
Gee, P., Lung, M. S. Y., Okuzaki, Y., Sasakawa, N., Iguchi, T., Makita, Y., Hozumi, H., Miura, Y., Yang, L. F., Iwasaki, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14957-y · Cited by 362
Engineering of CRISPR-Cas12b for human genome editing
Strecker, J., Jones, S., Koopal, B., Schmid-Burgk, J., Zetsche, B., Gao, L., Makarova, K. S., Koonin, E. V., & Zhang, F. (2019) · Nature Communications · doi:10.1038/s41467-018-08224-4 · Cited by 358
Programmable CRISPR-responsive smart materials
English, M. A., Soenksen, L. R., Gayet, R. V., de Puig, H., Angenent-Mari, N. M., Mao, A. S., Nguyen, P. Q., & Collins, J. J. (2019) · Science · doi:10.1126/science.aaw5122 · Cited by 356
Karvelis, T., Bigelyte, G., Young, J. K., Hou, Z., Zedaveinyte, R., Budre, K., Paulraj, S., Djukanovic, V., Gasior, S., Silanskas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa208 · Cited by 349
A CRISPR-Cas autocatalysis-driven feedback amplification network for supersensitive DNA diagnostics
Shi, K., Xie, S., Tian, R., Wang, S., Lu, Q., Gao, D., Lei, C., Zhu, H., & Nie, Z. (2021) · Science Advances · doi:10.1126/sciadv.abc7802 · Cited by 334
“Given that Cas effectors could recognize, unwind, and bind any gene loci of interest under the guidance of gRNA (10, 25, 26), CRISPR-Cas systems provide a solution to address the limitation that conventional nucleic acid circuits lack recognition mechanisms for gene loci in genomic DNA.”
BackgroundMachine learning for metabolic engineering: A review
Lawson, C. E., Martí, J. M., Radivojevic, T., Jonnalagadda, S. V. R., Gentz, R., Hillson, N. J., Peisert, S., Kim, J., Simmons, B. A., Petzold, C. J., et al. (2021) · Metabolic Engineering · doi:10.1016/j.ymben.2020.10.005 · Cited by 313
“Moreover, CRISPR-based tools (Doudna and Charpentier, 2014; Knott and Doudna, 2018) provide easy DNA editing and metabolic perturbations (e.”
MethodUniversal CARs, universal T cells, and universal CAR T cells
Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 310
Feng, W., Newbigging, A. M., Tao, J., Cao, Y., Peng, H., Le, C., Wu, J., Pang, B., Li, J., Tyrrell, D. L., et al. (2021) · Chemical Science · doi:10.1039/d0sc06973f · Cited by 312
DNA hydrogel-based gene editing and drug delivery systems
Mo, F., Jiang, K., Zhao, D., Wang, Y., Song, J., & Tan, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.018 · Cited by 304
Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning
Arbab, M., Shen, M. W., Mok, B., Wilson, C., Matuszek, Ż., Cassa, C. A., & Liu, D. R. (2020) · Cell · doi:10.1016/j.cell.2020.05.037 · Cited by 294
“Editing of targeted nucleotides in genomic DNA is a key capability for both research and therapeutic applications (Adli, 2018; Anzalone et al., 2019; Doench et al., 2016; Doudna and Knott, 2018; Pérez-Palma et al., 2019; Rees and Liu, 2018; Shen et al., 2018).”
BackgroundMultiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts
Campa, C. C., Weisbach, N. R., Santinha, A. J., Incarnato, D., & Platt, R. J. (2019) · Nature Methods · doi:10.1038/s41592-019-0508-6 · Cited by 286
A new era in functional genomics screens
Przybyla, L., & Gilbert, L. A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00409-w · Cited by 281
CRISPR-Cas based virus detection: Recent advances and perspectives
Yin, L., Man, S., Ye, S., Liu, G., & Ma, L. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113541 · Cited by 277
Micro‐Gel Ensembles for Accelerated Healing of Chronic Wound via pH Regulation
Cui, T., Yu, J., Wang, C., Chen, S., Li, Q., Guo, K., Qing, R., Wang, G., & Ren, J. (2022) · Advanced Science · doi:10.1002/advs.202201254 · Cited by 276
The science and medicine of human immunology
Pulendran, B., & Davis, M. M. (2020) · Science · doi:10.1126/science.aay4014 · Cited by 274
“This, coupledwith recent development of CRISPR-based high-throughput screens in primary cells, offers a potential way to rapidly screen and validate immune signatures (139).”
BackgroundNoncoding RNAs in cancer therapy resistance and targeted drug development
Wang, W.-T., Han, C., Sun, Y.-M., Chen, T.-Q., & Chen, Y.-Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0748-z · Cited by 265
“3(g)) [102], and other forms of small RNAs (sRNAs) [1, 6].”
BackgroundAccelerated RNA detection using tandem CRISPR nucleases
Liu, T. Y., Knott, G. J., Smock, D. C. J., Desmarais, J. J., Son, S., Bhuiya, A., Jakhanwal, S., Prywes, N., Agrawal, S., Díaz de León Derby, M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00842-2 · Cited by 268
Self-citationPrecise genomic deletions using paired prime editing
Choi, J., Chen, W., Suiter, C. C., Lee, C., Chardon, F. M., Yang, W., Leith, A., Daza, R. M., Martin, B., & Shendure, J. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01025-z · Cited by 251
Mustafa, M. I., & Makhawi, A. M. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00745-20 · Cited by 232
RetractedCRISPR Mediated Biosensing Toward Understanding Cellular Biology and Point‐of‐Care Diagnosis
Dai, Y., Wu, Y., Liu, G., & Gooding, J. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005398 · Cited by 242
High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects
Tong, H., Huang, J., Xiao, Q., He, B., Dong, X., Liu, Y., Yang, X., Han, D., Wang, Z., Wang, X., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01419-7 · Cited by 230
Polymeric vehicles for nucleic acid delivery
Piotrowski-Daspit, A. S., Kauffman, A. C., Bracaglia, L. G., & Saltzman, W. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.014 · Cited by 224
“The CRISPR/Cas9 system has been the most widely used gene editing approach since its discovery in 2013, in part due to the relative ease of design for various applications [15].”
MethodIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
CRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 208
Current state and future prospects of pure mycelium materials
Vandelook, S., Elsacker, E., Van Wylick, A., De Laet, L., & Peeters, E. (2021) · Fungal Biology and Biotechnology · doi:10.1186/s40694-021-00128-1 · Cited by 195
“A recent leap forward in targeted genetic modification was made possible with the development of CRISPR/Cas9 as a versatile genetic engineering tool [65, 66].”
BackgroundZhang, M., Wang, H., Wang, H., Wang, F., & Li, Z. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00686 · Cited by 213
Park, J. H., Jiang, Y., Zhou, J., Gong, H., Mohapatra, A., Heo, J., Gao, W., Fang, R. H., & Zhang, L. (2021) · Science Advances · doi:10.1126/sciadv.abf7820 · Cited by 206
“A wide range of tools are available to introduce or upregulate the expression of specific surface markers (34, 35), and this approach enables researchers to augment the functionality of cell membrane–based nanodelivery platforms based on application specific needs (36, 37).”
BackgroundComputational approaches for effective CRISPR guide RNA design and evaluation
Liu, G., Zhang, Y., & Zhang, T. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.11.006 · Cited by 201
“This advancing technology is increasingly being deployed, and has great potential for clinical detection, gene therapy and agricultural improvement [3,21,50,126].”
BackgroundLiu, Y., Zou, R. S., He, S., Nihongaki, Y., Li, X., Razavi, S., Wu, B., & Ha, T. (2020) · Science · doi:10.1126/science.aay8204 · Cited by 196
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 173
“, 2022), a concept that represents a promising therapeutic strategy for the long-term correction of genetic illnesses (Knott and Doudna, 2018).”
BackgroundThe importance of genomic variation for biodiversity, ecosystems and people
Stange, M., Barrett, R. D. H., & Hendry, A. P. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00288-7 · Cited by 190
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 175
DNA-guided DNA cleavage at moderate temperatures by Clostridium butyricum Argonaute
Hegge, J. W., Swarts, D. C., Chandradoss, S. D., Cui, T. J., Kneppers, J., Jinek, M., Joo, C., & van der Oost, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz306 · Cited by 199
Structural biology of CRISPR–Cas immunity and genome editing enzymes
Wang, J. Y., Pausch, P., & Doudna, J. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00739-4 · Cited by 187
Self-citationRational designs of in vivo CRISPR-Cas delivery systems
Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 184
Genetic Engineering of Bacteriophages Against Infectious Diseases
Chen, Y., Batra, H., Dong, J., Chen, C., Rao, V. B., & Tao, P. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00954 · Cited by 168
CRISPR‐Cas‐based detection for food safety problems: Current status, challenges, and opportunities
Li, Y., Man, S., Ye, S., Liu, G., & Ma, L. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13000 · Cited by 173
A catalogue of biochemically diverse CRISPR-Cas9 orthologs
Gasiunas, G., Young, J. K., Karvelis, T., Kazlauskas, D., Urbaitis, T., Jasnauskaite, M., Grusyte, M. M., Paulraj, S., Wang, P.-H., Hou, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19344-1 · Cited by 177
Structures, mechanisms and applications of RNA-centric CRISPR–Cas13
Yang, H., & Patel, D. J. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01593-6 · Cited by 163
Willems, J., de Jong, A. P. H., Scheefhals, N., Mertens, E., Catsburg, L. A. E., Poorthuis, R. B., de Winter, F., Verhaagen, J., Meye, F. J., & MacGillavry, H. D. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000665 · Cited by 170
“Targeted gene editing using CRISPR/Cas9 facilitates the introduction of donor DNA at specific loci in the genome, effectively tagging endogenous proteins of interest [15,16].”
BackgroundHu, M., Liu, R., Qiu, Z., Cao, F., Tian, T., Lu, Y., Jiang, Y., & Zhou, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300663 · Cited by 170
An Integrated Index: Engrams, Place Cells, and Hippocampal Memory
Goode, T. D., Tanaka, K. Z., Sahay, A., & McHugh, T. J. (2020) · Neuron · doi:10.1016/j.neuron.2020.07.011 · Cited by 159
Deng, F., Li, Y., Yang, B., Sang, R., Deng, W., Kansara, M., Lin, F. P. Y., Thavaneswaran, S., Thomas, D. M., & Goldys, E. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46001-8 · Cited by 180
Dolan, A. E., Hou, Z., Xiao, Y., Gramelspacher, M. J., Heo, J., Howden, S. E., Freddolino, L., Ke, A., & Zhang, Y. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.014 · Cited by 158
“The utilization of Cas9 and Cas12 (Class 2, Type II and V effectors, respectively) for RNAguided eukaryotic genome editing has revolutionized biomedical research and precision medicine (Cong et al., 2013; Jinek et al., 2012; Knott and Doudna, 2018; Mali et al., 2013; Zetsche et al., 2015).”
BackgroundMethodOrganization and expression of the mammalian mitochondrial genome
Rackham, O., & Filipovska, A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00480-x · Cited by 159
Ma, J., Lyu, Y., Liu, X., Jia, X., Cui, F., Wu, X., Deng, S., & Yue, C. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01799-0 · Cited by 142
A Lysosome‐Activated Tetrahedral Nanobox for Encapsulated siRNA Delivery
Gao, Y., Chen, X., Tian, T., Zhang, T., Gao, S., Zhang, X., Yao, Y., Lin, Y., & Cai, X. (2022) · Advanced Materials · doi:10.1002/adma.202201731 · Cited by 157
Signal Amplification by the trans -Cleavage Activity of CRISPR-Cas Systems: Kinetics and Performance
Feng, W., Zhang, H., & Le, X. C. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04555 · Cited by 167
Soybean Yield Formation Physiology – A Foundation for Precision Breeding Based Improvement
Vogel, J. T., Liu, W., Olhoft, P. M., Crafts‐Brandner, S. J., Pennycooke, J. C., & Christiansen, N. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.719706 · Cited by 181
“More recently another precision breeding technology, genome editing, has garnered much attention (Songstad et al., 2017; Knott and Doudna, 2018).”
BackgroundCRISPR-Cas12a has widespread off-target and dsDNA-nicking effects
Murugan, K., Seetharam, A. S., Severin, A. J., & Sashital, D. G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012933 · Cited by 151
“Cas9 cleavage specificity is not only dictated by position-specific mismatches but is also defined by the target sequence (20, 45).”
MethodInfluentialNoncanonical crRNAs derived from host transcripts enable multiplexable RNA detection by Cas9
Jiao, C., Sharma, S., Dugar, G., Peeck, N. L., Bischler, T., Wimmer, F., Yu, Y., Barquist, L., Schoen, C. U., Kurzai, O., et al. (2021) · Science · doi:10.1126/science.abe7106 · Cited by 160
Suea‐Ngam, A., Howes, P. D., & deMello, A. J. (2021) · Chemical Science · doi:10.1039/d1sc02197d · Cited by 154
Exploration of Plant-Microbe Interactions for Sustainable Agriculture in CRISPR Era
Shelake, R. M., Pramanik, D., & Kim, J. (2019) · Microorganisms · doi:10.3390/microorganisms7080269 · Cited by 153
“In this regard, GE tools are of great interest that allows scientists to edit genomic sequences in a more precise manner without the integration of a foreign gene [33].”
BackgroundMethodLampe, G. D., King, R. T., Halpin-Healy, T. S., Klompe, S. E., Hogan, M. I., Vo, P. L. H., Tang, S., Chavez, A., & Sternberg, S. H. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01748-1 · Cited by 145
“RNA-guided DNA endonucleases encoded by CRISPR–Cas systems offer ease of programmability and high-efficiency activity in a wide range of cells and organisms and have, therefore, experienced widespread adoption for basic research, agricultural applications and human therapeutics 1,2 .”
Li, F., Song, N., Dong, Y., Li, S., Li, L., Liu, Y., Li, Z., & Yang, D. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202116569 · Cited by 156
Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases
Wu, S.-S., Li, Q.-C., Yin, C.-Q., Xue, W., & Song, C.-Q. (2020) · Theranostics · doi:10.7150/thno.43360 · Cited by 131
“Extensive work is being done with CRISPR/Cas in disease research and recent reviews had summarized the advantages of CRISPR/Cas [76, 77].”
BackgroundNext-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 152
CRISPR-Cas in Streptococcus pyogenes
Rhun, A. L., Escalera-Maurer, A., Bratovič, M., & Charpentier, E. (2019) · RNA Biology · doi:10.1080/15476286.2019.1582974 · Cited by 162
CRISPR/Cas9 systems: Delivery technologies and biomedical applications
Du, Y., Liu, Y.-F., Hu, J., Peng, X.-X., & Liu, Z.-B. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100854 · Cited by 144
“Conversely, CRISPR/Cas9 technology holds promise as a potential solution for permanent correction of genetic diseases [9] .”
BackgroundStimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant
Nambiar, T. S., Billon, P., Diedenhofen, G., Hayward, S. B., Taglialatela, A., Cai, K., Huang, J.-W., Leuzzi, G., Cuella-Martin, R., Palacios, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11105-z · Cited by 129
Zhang, Y., & Zeng, L. (2020) · Plant Communications · doi:10.1016/j.xplc.2020.100041 · Cited by 144
“12 Plant Communications 1, 100041, July 13 2020 a 2020 The Autho based on validated PTM crosstalk paired with progress in experimental approaches, such as utilization of the CRISPR (clustered regularly interspaced short palindromic repeats) techniques (Knott and Doudna, 2018) in further characterizations of the PTMs d…”
MethodFeng, W., Peng, H., Xu, J., Liu, Y., Pabbaraju, K., Tipples, G. A., Joyce, M., Saffran, H. A., Tyrrell, D. L., Babiuk, S., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03456 · Cited by 137
Clinical applications for exosomes: Are we there yet?
Perocheau, D., Touramanidou, L., Gurung, S., Gissen, P., & Baruteau, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15432 · Cited by 123
“To counteract this, PEG-conjugated antibodies or “nanobodies” against EGFR are added onto the exosomal membrane increasing the circulation time and binding to EGFR overexpressing tumour cells (Kooijmans et al., 2016).”
BackgroundInner Ear Gene Therapies Take Off: Current Promises and Future Challenges
Delmaghani, S., & El-Amraoui, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072309 · Cited by 136
“Genome editing tools with higher levels of performance have progressively been developed, based on the use of ZFNs (zinc finger nucleases) [129], TALENs (transcription activator-like effector nucleases) [130], and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9),…”
BackgroundCRISPR/dCas-mediated transcriptional and epigenetic regulation in plants
Pan, C., Sretenovic, S., & Qi, Y. (2021) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2020.101980 · Cited by 132
Perspectives for self-driving labs in synthetic biology
Martín, H. G., Radivojević, T., Zucker, J., Bouchard, K. E., Sustarich, J. M., Peisert, S., Arnold, D., Hillson, N. J., Babnigg, G., Martí, J. M., et al. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102881 · Cited by 129
“Furthermore, the genome is now more accessible than ever before through recent advances in CRISPR-enabled gene-editing tools [22], and evolutionary approaches comprising, for example, targeted mutagenesis and natural selection [23,24].”
Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation
Liu, T. Y., & Doudna, J. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.007034 · Cited by 121
“Type III Csm or Cmr complexes recognize and degrade complementary target RNA (orange lines) (1), cleave ssDNA (red lines) nonspecifically when bound to an RNA target, possibly at exposed R-loops (2), and synthesize a second messenger molecule, cyclic oligoadenylate (cOA, gray diamonds), when bound to an RNA target (3).”
BackgroundSelf-citationGuo, Z., Sun, D., Kang, S., Zhou, J., Gong, L., Qin, J., Guo, L., Zhu, L., Bai, Y., Luo, L., et al. (2019) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2019.01.009 · Cited by 124
Evaluation of CRISPR/Cas12a-based DNA detection for fast pathogen diagnosis and GMO test in rice
Zhang, Y.-M., Zhang, Y., & Xie, K. (2020) · Molecular Breeding · doi:10.1007/s11032-019-1092-2 · Cited by 131
Machine learning predicts new anti-CRISPR proteins
Eitzinger, S., Asif, A., Watters, K. E., Iavarone, A. T., Knott, G. J., Doudna, J. A., & Minhas, F. U. A. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa219 · Cited by 121
“CRISPR–Cas systems use a combination of genetic memory and highly specific nucleases to form a powerful adaptive defense mechanism in bacteria and archaea (1–4).”
Self-citationWang, G., Tian, W., Liu, X., Ren, W., & Liu, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00680 · Cited by 125
Qin, J., Wang, W., Gao, L., & Yao, S. Q. (2022) · Chemical Science · doi:10.1039/d1sc06269g · Cited by 119
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 126
Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing
Adler, B. A., Hessler, T., Cress, B. F., Lahiri, A., Mutalik, V. K., Barrangou, R., Banfield, J., & Doudna, J. A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01258-x · Cited by 114
Self-citationNiu, T.-C., Lin, G.-M., Xie, L.-R., Wang, Z.-Q., Xing, W.-Y., Zhang, J.-Y., & Zhang, C.-C. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00437 · Cited by 117
Broad-spectrum enzymatic inhibition of CRISPR-Cas12a
Knott, G. J., Thornton, B. W., Lobba, M. J., Liu, J.-J., Al-Shayeb, B., Watters, K. E., & Doudna, J. A. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0208-z · Cited by 120
Self-citationCRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 117
Genome editing for horticultural crop improvement
Xu, J., Hua, K., & Lang, Z. (2019) · Horticulture Research · doi:10.1038/s41438-019-0196-5 · Cited by 126
Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 130
Metadata
- Authors
- Knott, G. J., & Doudna, J. A.
- Affiliations
- University of California, Berkeley (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Doudna, Jennifer A.
- Venue
- Science
- Published
- 2018-08-31
- Volume
- 361
- Issue
- 6405
- Pages
- 866-869
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6455913
- OpenAlex
- W2888908334
- Cited by
- 1,410
- References
- 76
- Citations by year
- 2026: 92 · 2025: 155 · 2024: 169 · 2023: 177 · 2022: 214 · 2021: 223 · 2020: 205 · 2019: 149 · 2018: 23
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- CRISPR-Cas, genome editing, transcriptional regulation, CRISPR-Cas diagnostics, agricultural biotechnology
- MeSH terms
- Gene Editing, CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Animals, Bacterial Proteins, DNA, Endonucleases, Genetic Engineering, Humans, Plants, RNA, Transcription, Genetic, Molecular Imaging, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.